Multidisciplinary care that includes growth hormone treatment should not cease once patients with Prader-Willi syndrome reach adulthood, according to authors of a study on care outcomes. There is a ...

Findings showed DCCR significantly improved hyperphagia in patients with severe hyperphagia at baseline. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

The FDA granted orphan drug designation to an investigational drug for the treatment of Prader-Willi syndrome, according to an industry press release. Tesomet (Saniona) is an investigational, ...

Children with Prader–Willi syndrome (PWS) receive growth-hormone (GH) replacement therapy. Small studies suggested that GH administration might also benefit adults with PWS; however, GH has multiple ...

Patients with Prader-Willi syndrome showed early signs of microvascular disease upon screening. In a study using urinalysis screening to detect microvascular disease, 1 in 5 adults with Prader-Willi ...

A Prescription Drug User Fee Act target date of December 27, 2024 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS ...

How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP ...

REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...